CIBC Asset Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$188M Buy
747,319
+47,137
+7% +$10.1M 0.41% 51
2026
Q1
$152M Buy
700,182
+12,103
+2% +$2.68M 0.37% 53
2025
Q4
$157M Buy
688,079
+367,172
+114% +$83.6M 0.38% 51
2025
Q3
$74.3M Buy
320,907
+2,466
+0.8% +$502K 0.22% 79
2025
Q2
$59.1M Sell
318,441
-16,877
-5% -$3.14M 0.18% 92
2025
Q1
$70.2M Buy
335,318
+512
+0.2% +$99.5K 0.23% 80
2024
Q4
$59.5M Sell
334,806
-27,536
-8% -$5.06M 0.2% 87
2024
Q3
$71.5M Buy
362,342
+20,137
+6% +$3.76M 0.23% 78
2024
Q2
$58.7M Sell
342,205
-10,903
-3% -$1.81M 0.21% 81
2024
Q1
$64.3M Sell
353,108
-2,627
-0.7% -$453K 0.22% 83
2023
Q4
$55.1M Sell
355,735
-14,138
-4% -$2.06M 0.21% 84
2023
Q3
$55.1M Sell
369,873
-6,772
-2% -$994K 0.23% 81
2023
Q2
$50.7M Sell
376,645
-11,132
-3% -$1.63M 0.19% 93
2023
Q1
$61.8M Buy
387,777
+2,339
+0.6% +$358K 0.25% 75
2022
Q4
$62.3M Sell
385,438
-2,719
-0.7% -$417K 0.26% 74
2022
Q3
$52.1M Buy
388,157
+86,255
+29% +$12.4M 0.23% 76
2022
Q2
$46.2M Buy
301,902
+5,546
+2% +$847K 0.19% 84
2022
Q1
$48M Buy
296,356
+82,023
+38% +$11.9M 0.17% 85
2021
Q4
$29M Buy
214,333
+3,830
+2% +$452K 0.11% 123
2021
Q3
$22.7M Buy
210,503
+3,612
+2% +$413K 0.09% 141
2021
Q2
$23.3M Buy
206,891
+5,932
+3% +$668K 0.09% 133
2021
Q1
$21.7M Sell
200,959
-7,059
-3% -$755K 0.09% 133
2020
Q4
$22.3M Sell
208,018
-389
-0.2% -$37.4K 0.1% 130
2020
Q3
$18.3M Sell
208,407
-11,433
-5% -$1.08M 0.09% 133
2020
Q2
$21.6M Buy
219,840
+4,255
+2% +$375K 0.13% 109
2020
Q1
$16.4M Sell
215,585
-15,180
-7% -$1.29M 0.12% 117
2019
Q4
$20.4M Sell
230,765
-22,751
-9% -$1.89M 0.12% 92
2019
Q3
$19.2M Buy
253,516
+4,532
+2% +$311K 0.11% 92
2019
Q2
$18.1M Sell
248,984
-20,200
-8% -$1.59M 0.11% 89
2019
Q1
$21.7M Buy
269,184
+92,058
+52% +$7.53M 0.13% 80
2018
Q4
$16.3M Buy
177,126
+17,390
+11% +$1.53M 0.12% 84
2018
Q3
$15.1M Buy
159,736
+6,114
+4% +$580K 0.09% 96
2018
Q2
$14.2M Sell
153,622
-438
-0.3% -$42.8K 0.09% 100
2018
Q1
$14.6M Sell
154,060
-27,186
-15% -$2.99M 0.09% 96
2017
Q4
$17.5M Sell
181,246
-62,297
-26% -$5.87M 0.11% 90
2017
Q3
$21.6M Buy
243,543
+16,779
+7% +$1.28M 0.14% 73
2017
Q2
$16.4M Sell
226,764
-5,051
-2% -$340K 0.11% 89
2017
Q1
$15.1M Buy
231,815
+3,925
+2% +$247K 0.1% 91
2016
Q4
$14.3M Buy
227,890
+5,524
+2% +$337K 0.1% 93
2016
Q3
$14M Sell
222,366
-4,690
-2% -$304K 0.1% 87
2016
Q2
$14.1M Buy
227,056
+14,632
+7% +$892K 0.11% 93
2016
Q1
$12.1M Buy
212,424
+65,115
+44% +$3.63M 0.09% 96
2015
Q4
$8.73M Sell
147,309
-9,351
-6% -$539K 0.07% 126
2015
Q3
$8.52M Buy
156,660
+1,877
+1% +$122K 0.07% 123
2015
Q2
$10.4M Buy
154,783
+17,592
+13% +$1.15M 0.07% 112
2015
Q1
$8.03M Buy
137,191
+5,053
+4% +$305K 0.06% 139
2014
Q4
$8.65M Sell
132,138
-35,441
-21% -$2.23M 0.06% 128
2014
Q3
$9.68M Sell
167,579
-25,963
-13% -$1.44M 0.06% 123
2014
Q2
$10.9M Sell
193,542
-2,638
-1% -$138K 0.06% 123
2014
Q1
$10.1M Sell
196,180
-41,364
-17% -$2.09M 0.06% 130
2013
Q4
$12.5M Sell
237,544
-11,482
-5% -$564K 0.08% 109
2013
Q3
$11.1M Sell
249,026
-17,938
-7% -$795K 0.07% 109
2013
Q2
$11M Buy
+266,964
New +$11.7M 0.08% 105

Other funds holding ABBV

CIBC Asset Management's ABBV Position: Q2 2026 in Review

CIBC Asset Management increased its AbbVie (ABBV) stake by 6.7% in Q2 2026, buying an estimated $10.1M and bringing the position to 747,319 shares worth $188M. The position accounts for 0.41% of the portfolio, ranked #51.

CIBC Asset Management first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 4,187 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • CIBC Asset Management held 747,319 shares of AbbVie worth $188M as of Q2 2026.
  • CIBC Asset Management bought 47,137 AbbVie shares in Q2 2026, an estimated $10.1M.
  • AbbVie made up 0.41% of CIBC Asset Management's portfolio in Q2 2026, its #51 holding.
  • CIBC Asset Management first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • 4,187 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on CIBC Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.